EAM
NUVB icon

Exos Asset Management’s Nuvation Bio NUVB Stock Holding History

Exos Asset Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-29,982
Closed -$279K – 615
2021
Q2 		$279K Buy
+29,982
New +$342K 0.14% 225
2021
Q1 		– Sell
-700
Closed -$8K – 447
2020
Q4 		$8K Buy
+700
New +$7.28K 0.01% 225

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Exos Asset Management's NUVB Position: Q3 2021 in Review

Exos Asset Management sold out of Nuvation Bio (NUVB) in Q3 2021, closing a stake of 29,982 shares — an estimated $279K sold.

Exos Asset Management first reported a position in NUVB in Q4 2020 and held it in 2 quarters. The position peaked at $279K in Q2 2021. 98 funds tracked by Wall St. Rank hold NUVB as of Q3 2021.

  • Exos Asset Management reported no remaining Nuvation Bio position as of Q3 2021 after selling out during the quarter.
  • Exos Asset Management sold 29,982 Nuvation Bio shares in Q3 2021, an estimated $279K.
  • Exos Asset Management first reported a position in Nuvation Bio in Q4 2020 and held it in 2 quarters.
  • Exos Asset Management's Nuvation Bio position peaked at $279K in Q2 2021.
  • 98 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2021.

Based on Exos Asset Management's 13F filing for Q3 2021, filed 25 Oct 2021.